Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China-Reference-Cited by-同舟云学术

Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China

Published:2023-07-14 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Ma Yuan¹,Li Juan²³,Cao Yanlin¹,Li Wei⁴,Shi Rujing⁵,Jia Bin⁶,Wang Haihong⁷,Yan Le⁸,Suo Luodan²,Yang Weizhong¹,Wu Jiang²,Feng Luzhao¹^ORCID

Affiliation:

1. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2. Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing, China

3. School of Public Health, Capital Medical University, Beijing, China

4. Center for Applied Statistics and School of Statistics, Renmin University of China, Beijing, China

5. Department of programmed immunization, Haidian District Center for Diseases Control and Prevention, Beijing, China

6. Department of programmed immunization, Chaoyang District Center for Diseases Control and Prevention, Beijing, China

7. Department of programmed immunization, Changping District Center for Diseases Control and Prevention, Beijing, China

8. Department of programmed immunization, Huairou District Center for Diseases Control and Prevention, Beijing, China

Funder

Chinese Academy of Medical Sciences

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2235963

Reference35 articles.

1. Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines

2. COVID-19: Understanding the New Variants of Concern

3. Role of COVID-19 Vaccines in SARS-CoV-2 Variants

4. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

5. Walensky RP. CDC recommends Pfizer booster at 5 months additional primary dose for certain immunocompromised children. 2022 Jan 4 [accessed 2022 Dec 21]. https://stacks.cdc.gov/view/cdc/113081.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice;Vaccine: X;2024-10

2. Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study;eClinicalMedicine;2024-01